Andrew Allen, MD, PhD
Co-founder, President and Chief Executive Officer,
Gritstone
Andrew Allen, M.D., Ph.D. co-founded Gritstone bio, Inc. and has served as President, CEO and a board member since 2015. In 2009, Dr. Allen co-founded Clovis Oncology and served as Chief Medical Officer until 2015, driving development of Rucaparib, a PARP inhibitor. Prior he was Chief Medical Officer at Pharmion Corporation, developing Vidaza, the first approved DNA methylation inhibitor, until acquisition by Celgene in 2008. Dr. Allen also served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company. He currently serves on the board of directors of TCR2 Therapeutics and Sierra Oncology (both public biopharma companies) and Revitope Oncology and Verge Genomics (both private biopharma companies). He previously served on the board of directors of Epizyme (developers of the first approved histone methylation transferase inhibitor) and Cell Design Labs (acquired by Gilead Sciences in 2017). Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College of Science, Technology and Medicine in London.
Sessions